Skip to main content
. 2026 Jan 30;17:1714022. doi: 10.3389/fimmu.2026.1714022

Figure 6.

Flow cytometry analysis of NK cells treated with IL-15 and various antibodies, showing CD107a expression (A) and Annexin V expression (B). The bar graphs indicate significant increases in CD107a and Annexin V levels in NK cells treated with IL-15 and daratumumab compared to other conditions. Color-coded bars represent different treatments: blue (IL-15), red (IL-15 + trastuzumab), green (IL-15 + TAB16), and purple (IL-15 + daratumumab), with statistical significance denoted by asterisks.

TAB16 does not induce NK cell fratricide. (A) Enriched NK cells (>90%) were incubated with IL-15 (10 ng/ml), +/- trastuzumab (5 μg/ml), TAB16 (33 nM), or daratumumab (5 μg/ml) for 5 hours. NK cells were stained for CD3, CD56, CD107a, and live/dead discrimination (live, CD56+ CD3–, CD107a+ cells graphed). Representative flow plots (left panels) and cumulative data (right panel). (B) Enriched NK cells (>95%) were incubated with IL-15 (10 ng/ml), +/- trastuzumab (5 μg/ml), TAB16 (33 nM), or daratumumab (5 μg/ml) for 24 hours. NK cells were stained for CD3, CD56, Annexin V, live/dead discrimination (CD56+ CD3–, Annexin V+ cells graphed). Representative flow plots (left panels) and cumulative data (right panel). Mean +/- SD, n = 3. *p<0.05; ns, not significant. Statistical significance was determined by one-way ANOVA with a Tukey post hoc test.